What changed, and when did screening start?
The WTA introduced mandatory SRY gene screening under its updated women's eligibility policy in 2026. The final policy took effect on July 21, and Jessica Pegula subsequently confirmed that testing had begun at the Cincinnati Open in August. A positive screening result leads to further medical assessment; it does not, by itself, establish that someone has received a permanent ban.
The change has generated several overlapping debates: how women's competition should define eligibility, what a genetic marker can establish, how sensitive information is handled, and whether players were adequately consulted. Those questions deserve separate answers. Agreement with a fairness objective does not necessarily mean agreement with every testing procedure, just as criticism of the procedure does not tell us a person's view on every eligibility rule.
Effective date versus rollout
The WTA's published rules page links the operative policy. Its July 21 effective date should take priority over an earlier date circulated during initial reporting. A rule's effective date, the first collection of samples and the completion of an individual assessment are different milestones.
In an August 12 interview, later updated August 17, Pegula told Front Office Sports that screening had started in Cincinnati. That establishes implementation had begun. It does not establish that every player had already been tested, that every assessment had finished, or that a publicly announced universal deadline existed.
As of September 6, 2026, readers should therefore describe the policy as implemented and screening as underway, without adding an unsupported total. The distinction matters when an older announcement is shared as if it described the latest operational position.
Which competition does the policy cover?
The document governs eligibility within the WTA's jurisdiction. It should not be treated as a substitute for reading another governing body's rules. A reference to women's tennis, the Olympics or a Grand Slam does not automatically mean the same administrator, procedure or appeal route applies.
Sky Sports' announcement report describes the move away from the previous hormone-based pathway for transgender women. The WTA presents the new framework as protecting fair competition. That is the organization's rationale, while the scientific and practical arguments about its chosen mechanism remain part of the public debate.
What does an SRY test actually measure?
SRY screening looks for a particular gene. It is not a direct measurement of someone's serve speed, endurance, match-winning ability or gender identity. Keeping the laboratory question separate from the sporting decision makes the rest of the policy easier to understand.
Gene presence is not a complete developmental history
MedlinePlus explains that SRY provides instructions for a protein involved in male-typical sex development. It is normally associated with the Y chromosome. However, gene variants can affect how the protein functions, and SRY can sometimes be transferred to another chromosome. A detected marker therefore does not describe every aspect of a person's chromosomes or development.
For example, MedlinePlus describes SRY-related forms of Swyer syndrome in which an individual with an XY chromosome pattern develops female-typical characteristics. It also describes cases in which SRY is present on an X chromosome. These are explanations of biological variation, not predictions about anyone on the tennis tour.
A second distinction concerns how the body responds to hormones. Androgen insensitivity syndrome involves reduced or absent responsiveness to androgens. Complete and partial forms are different. The word complete is therefore consequential when a sporting policy refers to complete androgen insensitivity; it should not disappear when that provision is summarized.
None of these examples permits a spectator to diagnose an athlete. A name, a photograph, a powerful forehand or a comment made at a press conference supplies no basis for deciding whether a person has one of these conditions.
Genetic screening and hormone testing ask different questions
The WTA's screening procedure can use a cheek swab, saliva or blood sample. The sample type does not change the central purpose: checking for SRY. That is different from measuring a hormone concentration at the time a sample is collected.
This distinction also prevents confusion with anti-doping language. A positive SRY screen is not a finding that a player used a prohibited substance. Calling it a failed drugs test would introduce an allegation the screening result does not establish.
There are three separate judgments here: whether a laboratory detected the marker, how the relevant biological history is understood, and how a governing body's eligibility criteria apply. A laboratory answer can be accurate while the choice of sporting criteria remains disputed. Conversely, supporting a competition category does not answer every question about the best way to administer it. The disagreement is partly about that connection between evidence and rulemaking, rather than simply whether laboratories can detect a gene.
What happens after a negative or positive result?
A negative screen ordinarily allows a player to compete, with screening intended to be once in a lifetime unless there is reason to suspect an erroneous negative result. A positive screen means the player cannot compete pending further medical assessment. Other eligibility requirements still matter, so neither sentence should be detached from the complete framework.
Assessment and the exception pathway
Ben Rothenberg's initial reporting describes the exception pathway, which also appears in the final policy. The player must satisfy the WTA Medical Manager that complete androgen insensitivity or another relevant developmental condition means they never experienced the physiological effects of either the policy-defined male mini-puberty in infancy or male adolescent puberty.
The burden is on the player to establish that exception. Assessment may involve medical history, further testing and expert input. Having a difference of sex development is therefore not an automatic exemption. Equally, the existence of a positive screen does not settle whether the exception applies.
This is why a headline about a positive result would require careful follow-up. Is the report describing an initial screen, an assessment still in progress, a reasoned eligibility decision or an appeal? Those stages have different consequences. Treating the first as the last would erase the assessment that the rules themselves provide.
The policy's use of biological categories is a definition for administering its competition rules. It should be attributed as such, rather than presented as a complete medical account of every possible variation in sex development or as a judgment about someone's identity.
Previous androgen treatment is a separate provision
The final framework also addresses players classified as biological females under its definitions who previously used testosterone or another androgen as part of gender-related treatment: four years must have passed since the last such use. That is a specific condition, not a general statement that all medications carry a four-year exclusion.
For a reader comparing the old and new systems, the practical point is that simply referring to a present hormone level does not describe the new exception test. Nor can a spectator apply the rule from a biography or a photograph. The relevant assessment depends on information that is not normally available to the public.
A player facing an actual decision needs the governing document and the appropriate professional support. A fan needs enough procedural context to avoid turning incomplete information into a confident allegation.
What protections, support and appeals does the policy provide?
The consequences of an eligibility process extend beyond the time needed to collect a sample. Players may need to understand consent, obtain advice and assess how a decision affects competition. Those issues help explain why the debate cannot be resolved solely by saying a cheek swab is quick.
Confidentiality and dignity
The policy requires confidential handling of medical information, with limited exceptions for implementation and legal obligations. It also addresses harassment based on eligibility or appearance. The WTA pays for required screening and medical assessments, and provides appropriate counselling support when requested during an assessment.
These provisions are significant, but a written protection and proof of its practical effectiveness are different things. A reasonable public question is how athletes are informed about access to their data. It is not reasonable to demand that a named athlete publish those data to reassure strangers.
The Sport & Rights Alliance's August 13 statement argues that mandatory screening risks stigma, privacy harms and distress, and calls for a pause and broader consultation. Those are the alliance's concerns and demands, not a court finding that a particular player's rights have been violated.
Supporters and critics can also mean different things by a simple process. A laboratory collection might be uncomplicated while questions about consent, future use of information or the consequences of an unexpected result remain difficult. Evaluating those questions does not require assuming that every participant has the same experience.
Challenging a decision
The policy distinguishes individual appeals to the Court of Arbitration for Sport from challenges to the policy's validity or legality, which it assigns to courts in Saint Petersburg, Florida. Filing a challenge does not automatically suspend the relevant rule or decision.
For readers following a future dispute, that distinction changes what a headline means. An appeal about whether a criterion was correctly applied to one person is not necessarily an attempt to invalidate the entire framework. Conversely, criticism of the framework is not evidence that a particular player's assessment was incorrectly performed.
It is also worth asking what a reported outcome actually resolves. A procedural decision, an interim order and a final merits ruling answer different questions. Describing each accurately leaves room for legitimate scrutiny without pretending that every legal development settles the whole debate.
The full terms remain important for anyone directly affected. For public discussion, the essential standard is narrower: assess the institution's rules and conduct with evidence, while respecting the personal information that an athlete is not obliged to share with an audience.
What have players and critics said?
Player reactions do not fit neatly into two camps. Some comments concern the principle of eligibility, others the process of consultation, and others the way the debate affects transgender people. Reading the complete position is more informative than assigning a player a label from a single sentence.
Coco Gauff's position combines fairness and trans rights
In comments reported from Toronto in August, Gauff supported fairness in women's sport while also supporting the transgender community and objecting to hostility directed at it. She raised a separate communication concern: some players she had spoken with learned of the decision through the public announcement.
Tennis Now's account of Gauff's remarks makes that combination clear. Describing her only as supporting the policy loses her concern about how the issue is used to attack people. Describing her only as opposing it loses her stated support for competitive fairness.
Other players emphasized different concerns
In the same report, Elena Rybakina said tennis had been fine without the tests but that players would comply if required. Belinda Bencic expressed support for the WTA's decision. Those responses illustrate the difference between accepting a requirement, considering it necessary and actively endorsing it.
Pegula, a Players' Council member, later told Front Office Sports that discussions and educational information had circulated over the preceding year. She said she had not heard complaints about the initial testing process. That is useful firsthand testimony about what she had heard; it is not a survey establishing unanimous approval across the tour.
There is no need to force Gauff's communication concern and Pegula's account of discussions into a claim that one must be lying. They describe different perspectives on how information reached players. The substantive question is whether communication was sufficiently broad and clear, not whether any conversation ever occurred.
The advocacy criticism discussed above adds another perspective: whether the policy's design and safeguards adequately protect affected people. Player interviews, medical explanations and rights arguments perform different roles. None should be presented as a replacement for the others, and none establishes private information about the person expressing the view.
How should fans interpret future updates?
The most useful next update would explain what has changed since the initial rollout. A new interview can add experience without changing the rule. An advocacy statement can request a change without securing one. A revised official document can change the framework even if an older news report continues circulating.
Identify the type of development
- A policy amendment: look for revised wording and an effective date, rather than assuming a critical comment has altered eligibility.
- An implementation update: distinguish collection arrangements or education from changes to the substantive criteria.
- An individual decision: establish the procedural stage and the scope of any confirmed public statement.
- A player reaction: preserve its date and context instead of presenting one interview as the view of the entire tour.
The official rules page is the starting point for the first category. Direct interviews are valuable for the second and fourth, but cannot replace a governing document when the question is what the rule requires. This division helps readers assess a report without expecting every source to answer every question.
Ask public questions that respect private information
There are useful questions an institution can address without publishing anyone's genetic results. How are new entrants informed? What guidance explains the assessment process? How are players told who may access their information? What opportunities exist to provide feedback on implementation?
These are questions about administration, not claims that the WTA has promised a particular report or failed a particular obligation. Aggregate information and clear procedures can inform public debate while preserving a boundary around personal medical details.
For the sporting side of the season, use the WTA tournament calendar and today's WTA matches. An entry list or withdrawal is not a medical disclosure. Follow confirmed competition news on its own terms, and assess policy developments through the documents and statements that actually address them.